News
2010 | 2009 | 2008 | 2007 | 2006
London, 18 December 2007
Directors’ Dealing
Powe Capital increases stake in ImmuPharma to over 5%
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), announces today that Powe Capital, through its funds Modulus Europe and Tensor Europe, has increased its stake in ImmuPharma from 3.12% to 5.59% through a purchase, on 14 December 2007, of 1,800,000 existing ordinary shares of 10 pence each in the Company from the Trusts of two of ImmuPharma's founders and Directors, Richard Warr and Dimitri Dimitriou.
London, 6 December 2007
Initiation of Phase IIb trials for IPP - 201101 in patients with Lupus; Allows earlier release of efficacy data in mid 2008
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, announces today that following its discussions with the US Food and Drug Administration ("FDA"), it has obtained feedback that refines the phase II/III programme for IPP- 201101 in patients with Systemic Lupus Erythematosus. The outcome of this consultation with the regulator has been the segmenting of the development programme into separate phase IIb and phase III trials. The company had previously expected a single phase II/III trial in 240 patients over 12 months. The revised plans allow the company to have additional phase II data, which has the potential to enhance its commercial attractiveness, earlier than previously expected and continuing with a simpler phase III trial in Q3 2008, broadly in line with previous development timelines. ImmuPharma expects the first patients to be dosed into the phase IIb trials very shortly.
London, 16 November 2007
Appointment of NOMAD and corporate broker
ImmuPharma plc (LSE:IMM), the specialist drug discovery and development company, is pleased to announce the appointment of Panmure Gordon & Co as its NOMAD and corporate broker with immediate effect.
London, 28 September 2007
INTERIM RESULTS ANNOUNCEMENT
For the six month ended 30 June 2007
ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company is pleased to announce its interim results for the six months ended 30 June 2007.
INTERIM HIGHLIGHTS
• Submitted file to the FDA for phase II / III
programme for lead drug for
Lupus
• Discovered new lead drug candidate for inflammation
• Continued development progress of other R&D assets
• Appointed two board members with pharma industry experience
• Appointed Teather & Greenwood (now Landsbanki) as nominated
adviser and broker while retaining Dawnay, Day Corporate Finance as
joint financial adviser
• Cash and cash equivalents at 30th June 2007 were £4,826,994,
compared to £6,459,918 at 31st December 2006.
London, 22 August 2007
ImmuPharma discovers new lead drug candidate for inflammation
ImmuPharma plc (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today that following its discovery activities on its chemical library, it has discovered a new molecular series with potential application in inflammatory/allergic conditions such as asthma and rheumatoid arthritis. These molecules, in the programme code-named IPP-201007, have utility as selective phospholipase A2 subtype inhibitors and are already patented through ImmuPharma's library broad patent.
London, 20 August 2007
AIM Rule 26
ImmuPharma plc (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, today announces that the information required by Rule 26 of the AIM Rules for Companies (February 2007) is available in the investor section of the Company's website at www.immupharma.com/AIM_Rule_26_Information.html
London, 13 August 2007
Directors' Dealing
ImmuPharma plc (LSE:IMM),("ImmuPharma" or the "Company"), received notification of a private placement of existing shares to institutions and private investors, including Quest Management, Morley, Odey Asset Management, Cheviot and Celeste. The shares were placed to satisfy demand and increase liquidity, from the holdings of two of the founding Directors.
London, 10 July 2007
ImmuPharma submits file to the FDA for
pivotal phase II/III trial in Lupus patients
ImmuPharma plc (LSE:IMM),("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today that it has just submitted an IND (Investigational New Drug) file to the US Food and Drug Administration (FDA) for the initiation of a pivotal phase II/III trial for its drug IPP-201101 in patients suffering from Systemic Lupus Erythematosus.
London, 13 June 2007
PRELIMINARY RESULTS
AGM Statement and Board Update
ImmuPharma plc (LSE:IMM), the
specialist pharmaceutical discovery and development company, held its
AGM earlier today and is pleased to
announce that all resolutions were passed.
Paddy Walker-Taylor, 60, currently part-time finance director, has
decided by mutual agreement with the company to resign his role as
director but remain with the company on a reduced-time basis.
London, 1 May 2007
PRELIMINARY RESULTS
for the period ended 31st December 2006
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist pharmaceutical discovery and development company is pleased
to announce its preliminary results for the period ended 31st December
2006.
Key Highlights:
• Successful completion of Phase II trial of our lead compound
IPP-201101, for the treatment of Lupus.
• Positive discussions held with FDA and plans for a Phase II/III
multicentre study in the US and Europe.
• Cash reserves strengthened with a further €7m funds raised.
London, 27 April 2007
Board Appointment
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, today announces the appointment of Ajay Agrawal (42) as a non-executive director. Dr Agrawal has almost 20 years' experience in the biotech and pharmaceutical industry worldwide.
London, 15 February 2007
Appointment of adviser
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company is pleased to announce the appointment of Teather & Greenwood Limited as nominated adviser and broker. The appointment is with immediate effect.
Dawnay, Day Corporate Finance Limited continues to act for ImmuPharma plc as joint financial adviser.
London, 07 February 2007
Board Changes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announced today the following changes to its Board and a senior management appointment.
